Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Real-World Data Regarding Long-Term Administration of Natalizumab Derived from a Neurology Department along with Literature Review

Author(s): Eugenia Irene Davidescu, Irina Odajiu, Constantin-Dragoș Sandu, Amalia Ghergu, Dimela Luca, Dafin Fior Mureșanu and Bogdan Ovidiu Popescu*

Volume 21, Issue 4, 2022

Published on: 27 August, 2021

Page: [326 - 334] Pages: 9

DOI: 10.2174/1871527320666210827113733

Price: $65

Abstract

Background: Natalizumab is a humanized monoclonal antibody with high efficacy and an acceptable safety profile used in the treatment of patients with multiple sclerosis (MS).

Objective: Our aim was to report data regarding long-term administration of Natalizumab in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) from our clinic.

Methods: A retrospective observational study was performed including RRMS patients who underwent treatment with ≥ 24 Natalizumab infusions. We analyzed EDSS values, the relapse rate and the rate and type of adverse events related to Natalizumab administration.

Results: 51 subjects were included with a predominance of women (62.74%), with an average age of 40.43±1.49 years, a mean disease duration of 9.86±0.7 years and mean number of Natalizumab infusions of 45.58±2.74. An increased number of patients (80.39%) were relapse-free and a mild reduction of the mean EDSS value following Natalizumab initiation in patients who had not been treated with other disease modifying therapies anteriorly was observed. Among the encountered adverse events such as increased liver transaminases (13.72%), local infections (7.84%) and dysmenorrhea in one patient were registered in this study. The rate of severe adverse events was 3.92 and no cases of Progressive Multifocal Leukoencephalopathy (PML) were registered.

Conclusion: Natalizumab proves to be effective, has an adequate safety profile and can be administered with good tolerability for a rather extended period of time, provided that the patients are closely monitored.

Keywords: Natalizumab, long-term administration, efficacy, adverse reactions, multiple sclerosis, safety.

« Previous Next »
Graphical Abstract

[1]
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18(3): 269-85.
[http://dx.doi.org/10.1016/S1474-4422(18)30443-5] [PMID: 30679040]
[2]
Delbue S, Comar M, Ferrante P. Natalizumab treatment of multiple sclerosis: New insights. Immunotherapy 2017; 9(2): 157-71.
[http://dx.doi.org/10.2217/imt-2016-0113] [PMID: 28004598]
[3]
Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013; 333(1-2): 1-4.
[http://dx.doi.org/10.1016/j.jns.2013.05.010] [PMID: 23735777]
[4]
Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60(4): 577-84.
[http://dx.doi.org/10.1016/0092-8674(90)90661-W] [PMID: 1689216]
[5]
Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356(6364): 63-6.
[http://dx.doi.org/10.1038/356063a0] [PMID: 1538783]
[6]
Jain P, Coisne C, Enzmann G, Rottapel R, Engelhardt B. Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J Immunol 2010; 184(12): 7196-206.
[http://dx.doi.org/10.4049/jimmunol.0901404] [PMID: 20483748]
[7]
Clerico M, Artusi CA, Liberto AD, et al. Natalizumab in multiple sclerosis: long-term management. Int J Mol Sci 2017; 18(5): 940.
[http://dx.doi.org/10.3390/ijms18050940] [PMID: 28468254]
[8]
European Medicines Agency. Human medicines. 2006. Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri (Accessed September 15, 2020).
[9]
Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53(3): 466-72.
[http://dx.doi.org/10.1212/WNL.53.3.466] [PMID: 10449105]
[10]
Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348(1): 15-23.
[http://dx.doi.org/10.1056/NEJMoa020696] [PMID: 12510038]
[11]
Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72(9): 806-12.
[http://dx.doi.org/10.1212/01.wnl.0000343880.13764.69] [PMID: 19255407]
[12]
Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68(17): 1390-401.
[http://dx.doi.org/10.1212/01.wnl.0000260064.77700.fd] [PMID: 17452584]
[13]
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 911-23.
[http://dx.doi.org/10.1056/NEJMoa044396] [PMID: 16510745]
[14]
Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85(11): 1190-7.
[http://dx.doi.org/10.1136/jnnp-2013-306936] [PMID: 24532785]
[15]
van Pesch V, Bartholomé E, Bissay V, et al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: Subgroup analysis of the natalizumab observational program. Acta Neurol Belg 2014; 114(3): 167-78.
[http://dx.doi.org/10.1007/s13760-014-0308-9] [PMID: 24915752]
[16]
O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014; 83(1): 78-86.
[http://dx.doi.org/10.1212/WNL.0000000000000541] [PMID: 24898925]
[17]
Sousa L, de Sa J, Sa MJ, Cerqueira JJ, Martins-Silva A. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: A retrospective study. Rev Neurol 2014; 59(9): 399-406.
[PMID: 25342053]
[18]
Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol 2009; 16(3): 420-3.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02517.x] [PMID: 19364368]
[19]
Putzki N, Yaldizli O, Mäurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17(1): 31-7.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02728.x] [PMID: 19614963]
[20]
Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci 2011; 31(Suppl. 3): 299-302.
[http://dx.doi.org/10.1007/s10072-010-0344-z] [PMID: 20544247]
[21]
Krysko KM, O’Connor PW. The toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci 2011; 38(3): 422-8.
[http://dx.doi.org/10.1017/S0317167100011811] [PMID: 21515500]
[22]
Fernández O, Oreja-Guevara C, Arroyo R, Izquierdo G, Pérez JL, Montalban X. Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study. J Neurol 2012; 259(9): 1814-23.
[http://dx.doi.org/10.1007/s00415-012-6414-9] [PMID: 22289966]
[23]
Kallweit U, Jelcic I, Braun N, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: Real-life data from a Swiss cohort. Clin Neuropharmacol 2012; 35(2): 77-80.
[http://dx.doi.org/10.1097/WNF.0b013e31824644e6] [PMID: 22318192]
[24]
Totaro R, Lugaresi A, Bellantonio P, et al. Natalizumab treatment in multiple sclerosis patients: A multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol 2014; 27(2): 147-54.
[http://dx.doi.org/10.1177/039463201402700201] [PMID: 25004826]
[25]
Alroughani R, Al Hashel J, Thussu A, Ahmed SF. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait. Med Princ Pract 2013; 22(5): 495-9.
[http://dx.doi.org/10.1159/000351568] [PMID: 23797019]
[26]
De Stefano N, Stromillo ML, Giorgio A, et al. Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology 2015; 85(19): 1722-3.
[http://dx.doi.org/10.1212/WNL.0000000000002105] [PMID: 26468405]
[27]
Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72(2): 152-8.
[http://dx.doi.org/10.1001/jamaneurol.2014.3537] [PMID: 25531931]
[28]
Prosperini L, Fanelli F, Pozzilli C. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci 2016; 364: 145-7.
[http://dx.doi.org/10.1016/j.jns.2016.03.025] [PMID: 27084235]
[29]
Correia I, Batista S, Galego O, et al. Long-term effectiveness and safety of natalizumab in a Portuguese population. Int Immunopharmacol 2017; 46: 105-11.
[http://dx.doi.org/10.1016/j.intimp.2017.03.006] [PMID: 28282574]
[30]
Dekker I, Leurs CE, Hagens MHJ, et al. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. Mult Scler Relat Disord 2019; 33: 82-7.
[http://dx.doi.org/10.1016/j.msard.2019.05.017] [PMID: 31174043]
[31]
Bakshi R, Dandamudi VSR, Neema M, De C, Bermel RA. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimaging 2005; 15(4)(Suppl.): 30S-45S.
[http://dx.doi.org/10.1177/1051228405283901] [PMID: 16385017]
[32]
Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84(10): 1082-91.
[http://dx.doi.org/10.1136/jnnp-2012-304094] [PMID: 23524331]
[33]
Eisele P, Szabo K, Ebert A, Platten M, Gass A. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study. J Neuroimaging 2019; 29(2): 190-2.
[http://dx.doi.org/10.1111/jon.12586] [PMID: 30485572]
[34]
Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19(9): 1175-81.
[http://dx.doi.org/10.1177/1352458512473190] [PMID: 23319072]
[35]
Stephenson JJ, Kern DM, Agarwal SS, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study. Health Qual Life Outcomes 2012; 10: 155.
[http://dx.doi.org/10.1186/1477-7525-10-155] [PMID: 23270428]
[36]
Foley JF, Nair KV, Vollmer T, et al. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence 2017; 11: 1035-48.
[http://dx.doi.org/10.2147/PPA.S134865] [PMID: 28670113]
[37]
Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One 2013; 8(3): e58643-3.
[http://dx.doi.org/10.1371/journal.pone.0058643] [PMID: 23555589]
[38]
Wickström A, Dahle C, Vrethem M, Svenningsson A. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial. Mult Scler 2014; 20(8): 1095-101.
[http://dx.doi.org/10.1177/1352458513517590] [PMID: 24378984]
[39]
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910.
[http://dx.doi.org/10.1056/NEJMoa044397] [PMID: 16510744]
[40]
Sørensen PS, Jensen PEH, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011; 17(9): 1074-8.
[http://dx.doi.org/10.1177/1352458511404271] [PMID: 21511692]
[41]
Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007; 69(14): 1391-403.
[http://dx.doi.org/10.1212/01.wnl.0000277457.17420.b5] [PMID: 17761550]
[42]
Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013; 19(5): 593-600.
[http://dx.doi.org/10.1177/1352458512460604] [PMID: 22992450]
[43]
Shenoy ES, Mylonakis E, Hurtado RM, Venna N. Natalizumab and HSV meningitis. J Neurovirol 2011; 17(3): 288-90.
[http://dx.doi.org/10.1007/s13365-011-0027-4] [PMID: 21487835]
[44]
Kwiatkowski A, Gallois J, Bilbault N, Calais G, Mackowiak A, Hautecoeur P. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012; 18(6): 909-11.
[http://dx.doi.org/10.1177/1352458511428082] [PMID: 22048950]
[45]
Fragoso YD, Brooks JBB, Gomes S, de Oliveira FTM, da Gama PD. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther 2013; 19(4): 280-1.
[http://dx.doi.org/10.1111/cns.12067] [PMID: 23419219]
[46]
Antezana A, Sigal S, Herbert J, Kister I. Natalizumab-induced hepatic injury: A case report and review of literature. Mult Scler Relat Disord 2015; 4(6): 495-8.
[http://dx.doi.org/10.1016/j.msard.2015.08.008] [PMID: 26590653]
[47]
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353(4): 369-74.
[http://dx.doi.org/10.1056/NEJMoa051782] [PMID: 15947079]
[48]
Biogen IT. PML incidence in patients receiving Tysabri. 2016. Available from:http:medinfo.biogenidec.com Accessed September 15, 2020.
[49]
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366(20): 1870-80.
[http://dx.doi.org/10.1056/NEJMoa1107829] [PMID: 22591293]
[50]
MHRA. Natalizumab (Tysabri). Progressive Multifocal Leukoencephalopathy - updated advice to support early detection. 2016. Available from:www.gov.uk/drug-safetyupdate/natalizumab-tysabri-progressive-multifocalleukoencephalopathy-updated-advice-to-support-earlydetection Accessed September 16, 2020.
[51]
Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016; 9(9)(Suppl. 1): S5-S48.
[http://dx.doi.org/10.1016/j.msard.2016.07.003] [PMID: 27640924]
[52]
Tysabri FDA. Full prescribing information. 2008. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125104s106lbl.pdf Accessed September 16, 2020.
[53]
Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K. Real-World lab data in natalizumab treated multiple sclerosis patients up to 6 years long-term follow up. Front Neurol 2018; 9: 1071.
[http://dx.doi.org/10.3389/fneur.2018.01071] [PMID: 30581413]
[54]
Brown P, Zhou Y. RELISH Consortium. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database (Oxford) 2019; 2019: baz085.
[http://dx.doi.org/10.1093/database/baz085] [PMID: 33326193]

Rights & Permissions Print Cite
Article Metrics
31
4
© 2024 Bentham Science Publishers | Privacy Policy